201,609 Shares in Exelixis, Inc. $EXEL Purchased by Capital Impact Advisors LLC

Key Points

• Capital Impact Advisors LLC purchased 201,609 shares of Exelixis, Inc., valued at approximately $7.44 million, making it the firm's 18th largest holding.
• Exelixis reported earnings of $0.75 per share for the latest quarter, surpassing analysts' expectations of $0.63, although revenue declined by 10.8% year-over-year.
• Thirteen analysts rated Exelixis stock as a "Buy," while the consensus rating is currently a "Moderate Buy" with an average price target of $44.06.

Capital Impact Advisors LLC purchased a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 201,609 shares of the biotechnology company's stock, valued at approximately $7,443,000. Exelixis makes up about 2.9% of Capital Impact Advisors LLC's portfolio, making the stock its 18th biggest holding. Capital Impact Advisors LLC owned approximately 0.07% of Exelixis as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC lifted its stake in shares of Exelixis by 32.2% in the first quarter. GAMMA Investing LLC now owns 5,457 shares of the biotechnology company's stock worth $201,000 after acquiring an additional 1,328 shares in the last quarter. Park Avenue Securities LLC raised its stake in Exelixis by 10.6% during the first quarter. Park Avenue Securities LLC now owns 7,358 shares of the biotechnology company's stock valued at $272,000 after buying an additional 707 shares in the last quarter. Envestnet Asset Management Inc. raised its stake in Exelixis by 23.9% during the first quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company's stock valued at $9,159,000 after buying an additional 47,845 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new stake in Exelixis during the first quarter valued at approximately $233,000. Finally, Concurrent Investment Advisors LLC acquired a new stake in Exelixis during the first quarter valued at approximately $457,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on EXEL shares. Royal Bank Of Canada cut their price objective on Exelixis from $50.00 to $45.00 and set a "sector perform" rating on the stock in a research note on Tuesday, July 29th. Jefferies Financial Group set a $50.00 price objective on Exelixis and gave the company a "buy" rating in a research note on Tuesday, June 24th. Zacks Research cut Exelixis from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 26th. Bank of America upped their price objective on Exelixis from $45.00 to $46.00 and gave the company a "neutral" rating in a research note on Thursday, June 5th. Finally, Barclays upped their price objective on Exelixis from $29.00 to $40.00 and gave the company an "equal weight" rating in a research note on Thursday, July 10th. Thirteen equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Exelixis presently has a consensus rating of "Moderate Buy" and an average price target of $44.06.

Exelixis Trading Up 1.6%

NASDAQ:EXEL opened at $38.28 on Wednesday. The firm has a market capitalization of $10.31 billion, a PE ratio of 18.40, a price-to-earnings-growth ratio of 0.78 and a beta of 0.32. The stock has a 50 day moving average of $40.38 and a 200-day moving average of $39.61. Exelixis, Inc. has a 52 week low of $25.17 and a 52 week high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The business had revenue of $568.26 million during the quarter, compared to analyst estimates of $574.36 million. During the same period in the prior year, the company posted $0.84 EPS. The business's revenue for the quarter was down 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. As a group, analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.